Product information and disease descriptionProduct descriptionProduct information
Product comparison
18 evidence topics · 19 sources
Mevrometostat plus enzalutamide: randomized phase 1 dose expansion after abiraterone
Mevrometostat plus enzalutamide: dose escalation after abiraterone or enzalutamide
Mevrometostat 875 mg with food plus enzalutamide: safety and selection of the phase 3 dose
Mevrometostat 875 mg with food plus enzalutamide: efficacy after abiraterone, enzalutamide naive
Mevrometostat plus enzalutamide: MEVPRO-1 and MEVPRO-2 phase 3 designs
“MEVPRO-1 ( NCT06551324 ) is an open-label, phase III trial which will evaluate mevrometostat plus enzalutamide versus physician’s choice of either enzalutamide or docetaxel in patients with mCRPC who have progressed following ≥12 weeks of treatment with abiraterone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomization will be stratified by previous docetaxel in the metastatic castration-sensitive prostate cancer (mCSPC) setting, physician’s choice of comparator (prespecified prior to randomization and will remain consistent throughout the study), and presence of hepatic metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MEVPRO-2 ( NCT06629779 ) is a double-blind, placebo-controlled, phase III trial that will evaluate mevrometostat plus enzalutamide versus enzalutamide alone in adult patients with mCRPC who are treatment-naïve” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary efficacy endpoint for both MEVPRO-1 and MEVPRO-2 is rPFS per RECIST 1.1 (soft tissue) and PCWG3 (bone) assessed by BICR. OS (alpha protected) is a key secondary endpoint in both studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There will be no interim analysis for the primary endpoint (rPFS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mevrometostat plus enzalutamide: MEVPRO-1 enrollment and estimated primary completion
Mevrometostat plus enzalutamide: MEVPRO-3 in metastatic castration-sensitive disease
Tazemetostat plus enzalutamide: CELLO-1 randomized phase 2 after abiraterone
Tazemetostat: market withdrawal for hematologic second primary malignancies
Class concern for hematologic malignancy with chronic PRC2 inhibition in prostate cancer
“Mevrometostat, valemetostat, and tulmimetostat ( 18 – 20 ) have now been evaluated in several hundred patients. To date, no comparable secondary-malignancy signal has been publicly reported for these agents. This experience is reassuring but not yet definitive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the phase 1/2 mevrometostat experience, median follow-up was approximately 9.6 months as of the September 2, 2024 data cut ( 21 ) substantially shorter than the interval over which therapy-related MDS/AML typically emerge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All of these factors are possible mediators of risk, though no published data currently link any specific pharmacologic property to differential second-malignancy risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CPI-1205 plus enzalutamide or abiraterone: ProSTAR phase 1b/2
Company benchmark comparison: landmark rPFS and safety versus mevrometostat after abiraterone
| Regimen | Median follow-up | Month 3 rPFS | Month 4 rPFS | Month 5 rPFS | Grade 3 or higher TRAEs | Dose reductions / discontinuations |
|---|---|---|---|---|---|---|
| Mevrometostat 875 mg twice daily fed plus enzalutamide (n=14) | “9.2” months | “92%” | “92%” | “84%” | “36%” | “7% / 7%” |
| Mevrometostat 1250 mg twice daily fasted plus enzalutamide (n=41) | “11.7” months | “92%” | “86%” | “80%” | “49%” | “37% / 2%” |
| Enzalutamide monotherapy (n=40) | “9.0” months | “78%” | “70%” | “60%” | “23%” | “8% / 5%” |
| Rinzimetostat 400 mg once daily plus darolutamide (n=18) | “4.9” months | “93%” | “84%” | “84%” | “6%” | “None / 6%” |
Company benchmark comparison: serious adverse events and dose modifications versus mevrometostat
| Measure | Mevrometostat 875 mg twice daily fed plus enzalutamide (n=14) | Mevrometostat 1250 mg twice daily fasted plus enzalutamide (n=41) | Rinzimetostat 400 mg once daily plus darolutamide (n=18) |
|---|---|---|---|
| Grade 3 or higher TRAEs | “36%” | “49%” | “6%” |
| Serious TRAEs | “21%” | “24%” | “None” |
| Dose reductions | “7%” | “37%” | “None” |
| Treatment discontinuations | “7%” | “2%” | “6%” |
Company comparison of rPFS across post-ARPI therapies
| Treatment | Status | Month 5 rPFS | Median rPFS, months |
|---|---|---|---|
| Enzalutamide | “Approved” | “60%” | “6.2” |
| Cabazitaxel | “Approved” | “65%” | “8.0” |
| Docetaxel | “Approved” | “75%” | “8.3” |
| Lutetium Lu 177 vipivotide tetraxetan | “Approved” | “75%” | “9.3” |
| Mevrometostat plus enzalutamide | “Phase 3” | “80% to 84%” | “~12 to 14” |
| Rinzimetostat plus darolutamide | “Starting”“Phase 3” | “84% to 85%” | “Not mature” |
Company statements comparing dose optimization results with mevrometostat
Company comparison of PRC2 inhibitor development status
| Product | Development status |
|---|---|
| CPI-1205 | “Discontinued” |
| Tazemetostat | “Discontinued” |
| Mevrometostat | “Phase 3 trials ongoing” |
| Rinzimetostat | “First Phase 3 initiation expected 1H 2026” |